<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128579</url>
  </required_header>
  <id_info>
    <org_study_id>EQ001-19-002</org_study_id>
    <nct_id>NCT04128579</nct_id>
  </id_info>
  <brief_title>Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis</brief_title>
  <acronym>EQUALISE</acronym>
  <official_title>A Phase 1b Randomized, Double-blind, Placebo-controlled, Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Equillium</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Equillium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical
      activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without
      Active Proliferative Lupus Nephritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll up to 56 subjects, with up to 4 dose escalating cohorts of either 6
      open-label (Type A-SLE) or 8 double-blind (Type B-Lupus Nephritis) subjects (enrolled in a
      3:1 ratio). Subjects will receive itolizumab (Type A) or blinded itolizumab or placebo (Type
      B) administered subcutaneously every two weeks for a total of either 2 or 7 doses with 4 or
      12 weeks of follow-up after the last dose of investigational product.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>cohort based escalation of either 6 (Type A) or 8 (Type B) subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Type A is open-label. For Type B, there will be a designated unblinded individual (e.g. pharmacist) for drug preparation. Relevant vendors including PK will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum EQ001 serum concentration, Tmax</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Time to maximum EQ001 serum concentration, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum EQ001 serum drug concentration, Cmax</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Maximum EQ001 serum drug concentration, Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum EQ001 serum drug concentration, Cmin</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Minimum EQ001 serum drug concentration, Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total EQ001 exposure across time, AUC (from zero to infinity)</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Total EQ001 exposure across time, AUC (from zero to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of EQ001, t1/2</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Half life of EQ001, t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of EQ001, Vd</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Volume of distribution of EQ001, Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance, Cl</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Clearance, Cl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>Including but not limited to: IL-1β, IL-2, IL-6, IL-17, IL-21, IL-22, IL-23, IFN-γ, and TGF-β, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD6 receptor occupancy</measure>
    <time_frame>Type A Day 57 or Type B Day 169</time_frame>
    <description>the % levels of free versus EQ001-bound CD6 receptor on T cells</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>EQ001 Type A cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 4 cohorts with dosing to be determined in the range of 0.4 -- 2.4 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQ001 for Type B cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 7 doses (up to 4 cohorts with dosing to be determined in the range of 0.4 -- 2.4 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQ001 Placebo for Type B cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 7 doses (up to 4 cohorts with dosing to be determined in the range of 0.4 -- 2.4 mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itolizumab [Bmab 600]</intervention_name>
    <description>EQ001</description>
    <arm_group_label>EQ001 Type A cohort</arm_group_label>
    <arm_group_label>EQ001 for Type B cohort</arm_group_label>
    <other_name>Bmab600</other_name>
    <other_name>Itolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EQ001 Placebo</intervention_name>
    <description>EQ001 Placebo</description>
    <arm_group_label>EQ001 Placebo for Type B cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Type A Cohort Key Inclusion Criteria:

          1. Is male or female, age ≥ 18 and ≤ 75 years

          2. Has previously been documented to have met or currently meets Systemic Lupus
             International Collaborating Clinics (SLICC) and/or American College of Rheumatology
             (ACR) criteria for SLE

          3. Received at least 1 immunosuppressive or immunomodulatory treatment for SLE at any
             time in the past or currently

          4. Has documented elevation of antinuclear antibodies (ANA) in the past or during
             Screening

          5. Restricted SLE treatments are stable and/or washed out

          6. During Screening, has adequate hematologic function

        Type B Cohort Key Inclusion Criteria:

          1. Is male or female, age ≥ 18 and ≤ 75 years

          2. Meets SLICC and/or ACR criteria for SLE

          3. Kidney biopsy with a histologic diagnosis of LN Classes III or IV (+/- V)

          4. Has a urine protein to creatinine ratio of &gt; 1000 mg/g

          5. Meets criterion a and/or b

               1. Has previously completed induction treatment for active proliferative LN and is
                  currently receiving one of the following: mycophenolate mofetil (MMF),
                  mycophenolic acid (MPA), azathioprine or a calcineurin inhibitor.

               2. Has been receiving induction treatment with MMF/MPA and has a &lt; 50% reduction in
                  proteinuria at or after 12 weeks of induction

          6. During Screening has adequate hematologic function

          7. Restricted SLE treatments are stable and/or washed out

          8. Most recent eGFR ≥ 40 mL/min/1.73m2

          9. Has evidence of serologic activity during Screening

        Key Exclusion Criteria:

          1. Acute or chronic infections requiring systemic antibacterial, antifungal, or antiviral
             therapy

          2. Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV

          3. Active TB or a positive TB test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Kalunian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Kim</last_name>
    <phone>858 412 5302</phone>
    <email>clinicaltrials@equilliumbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765-2616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SouthCoast Research Center Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://equilliumbio.com/</url>
    <description>company website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Active Proliferative Lupus Nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

